Live Breaking News & Updates on Infectious diseases global

Stay informed with the latest breaking news from Infectious diseases global on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Infectious diseases global and stay connected to the pulse of your community

Virax Biolabs : Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 - Form 6-K

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

LONDON, April 25, 2024 /PRNewswire/ --...

Spain , London , City-of , United-kingdom , New-york , United-states , Barcelona , Comunidad-autonoma-de-cataluna , Virax-biolabs , James-foster , Nigel-mccracken , Nic-johnson

EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes - Virax Biolabs Group (NASDAQ:VRAX)

Unlock the potential of adaptive immunity with ImmuneSelect by Virax Biolabs. Investigate T-Cell driven immunity for post-viral syndromes like Long COVID. Explore peptide pools and recombinant antibodies for immune profiling.

James-foster , Virax-biolabs , Elispot-fluorospot , Nigel-mccracken , European-society-of-clinical-microbiology , Virax-biolabs-group-limited , Viraximmunet-cell , European-society , Clinical-microbiology , Infectious-diseases-global , Chief-executive-officer , Vitro-diagnostic

Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes

Thursday, Virax Biolabs Group Limited (NASDAQ: VRAX) announced it is launching ‘ImmuneSelect' within the ViraxImmune T-Cell diagnostic platform for…

Virax-biolabs-group-limited , European-society-of-clinical-microbiology , Viraximmunet-cell , European-society , Clinical-microbiology , Infectious-diseases-global , News , Ggregator , Reaking-news , Uration , Edia

Recombinant Zoster Vaccine Demonstrates High Protection Against Shingles in Adult Patients

The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.

Spain , Barcelona , Comunidad-autonoma-de-cataluna , Phil-dormitzer , Glaxosmithkline , Biomedical-research-of-the-valencian-community , Foundation-for-the-promotion-of-health , European-society-of-clinical-microbiology , Long-term-follow-up-study , Two-studies , Immunogenicity-persistence , Herpes-zoster-subunit

Positive Data Demonstrates Gepotidacin is Non-Inferior to Alternative Treatment in GC

In a trial that compared gepotidacin to ceftriaxone plus azithromycin in patients with urogenital gonorrhea, gepotidacin presented a 92.6% microbiological success rate.

Spain , Barcelona , Comunidad-autonoma-de-cataluna , Chris-corsico , European-society-of-clinical-microbiology , European-congress , Study-evaluating-efficacy , Uncomplicated-urogenital , European-society , Clinical-microbiology , Infectious-diseases-global , Infectious-diseases